The cellular homolog (c-fos) of the retroviral transforming gene, v-fos (occurring in FBJ-murine sarcoma virus) is expressed at high levels in a tissue- and stage-specific fashion during the development of murine embryos and occurs also in human fetal development. Extraembryonic tissues express the highest levels (placenta, amnion, visceral yolk sac, etc.), but fetal liver, bone marrow, and skin also express c-fos constitutively at lower levels. These examples and others in the literature demonstrate that c-fos expression can be activated by a variety of stimuli including growth factors, vitamin derivatives, and tumor promoters. In a variety of cell types, c-fos mRNA and protein expression are tightly regulated. The overall aim of this proposal is to study the mechanisms of control and the functions of c-fos with particular emphasis on its role in development. The following approaches will be used. 1) The function of fos will be directly tested by the introduction of """"""""anti-sense"""""""" and """"""""sense"""""""" fos recombinant DNA into embryonic cells of several types. Transcription of these gene sequences will prevent or enhance (respectively) c-fos expression. 2) c-Fos transcripts will be detected in individual cells and tissues by in situ hybridization of DNA probes to tissue sections and fixed cultured cells. 3) The possibility that the fos gene is activated by DNA demethylation will be investigated. 4) Using antibodies, the levels of fos protein in tissues and the basis for its post-translational modifications will be studied. The range of our present antibodies will be extended in order to follow the dynamics of fos protein regulation and to purity it from different sources. Viral oncogenes are intimately associated with cellular transformation and it is generally thought that the cellular proto-oncogenes also have growth-related functions. The presence of high levels of fos expression in embryonic tissues supports this idea. The studies proposed here take advantage of this to define the rules for its regulation and thereby help to point to a role for c-fos in normal or abnormal growth or differentiation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA067888-11
Application #
2390888
Study Section
Human Embryology and Development Subcommittee 1 (HED)
Project Start
1986-08-01
Project End
1999-03-31
Budget Start
1997-04-01
Budget End
1998-03-31
Support Year
11
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Sanford-Burnham Medical Research Institute
Department
Type
DUNS #
009214214
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Yu, J; Baron, V; Mercola, D et al. (2007) A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells. Cell Death Differ 14:436-46
Baron, V; Adamson, E D; Calogero, A et al. (2006) The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther 13:115-24
Subauste, M Cecilia; Nalbant, Perihan; Adamson, Eileen D et al. (2005) Vinculin controls PTEN protein level by maintaining the interaction of the adherens junction protein beta-catenin with the scaffolding protein MAGI-2. J Biol Chem 280:5676-81
Krones-Herzig, Anja; Mittal, Shalu; Yule, Kelly et al. (2005) Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53. Cancer Res 65:5133-43
Adamson, Eileen D; Yu, Jianxiu; Mustelin, Tomas (2005) Co-factors p300 and CBP catch Egr1 in their network. Prostate 63:407-10
Subauste, M Cecilia; Pertz, Olivier; Adamson, Eileen D et al. (2004) Vinculin modulation of paxillin-FAK interactions regulates ERK to control survival and motility. J Cell Biol 165:371-81
Hayakawa, Jun; Mittal, Shalu; Wang, Yipeng et al. (2004) Identification of promoters bound by c-Jun/ATF2 during rapid large-scale gene activation following genotoxic stress. Mol Cell 16:521-35
Yu, Jianxiu; de Belle, Ian; Liang, Hongyan et al. (2004) Coactivating factors p300 and CBP are transcriptionally crossregulated by Egr1 in prostate cells, leading to divergent responses. Mol Cell 15:83-94
Adamson, Eileen; de Belle, Ian; Mittal, Shalu et al. (2003) Egr1 signaling in prostate cancer. Cancer Biol Ther 2:617-22
Krones-Herzig, Anja; Adamson, Eileen; Mercola, Dan (2003) Early growth response 1 protein, an upstream gatekeeper of the p53 tumor suppressor, controls replicative senescence. Proc Natl Acad Sci U S A 100:3233-8

Showing the most recent 10 out of 24 publications